The company's first-quarter revenue slipped 0.3% year-over-year to $6.67 billion, while analysts surveyed by Visible Alpha ...

Gilead Sciences (NASDAQ: GILD) didn't have a bad first quarter, but investors didn't find it inspiring either. After ...

The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Its ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

Oppenheimer lowered the firm’s price target on Gilead (GILD) to $125 from $132 and keeps an Outperform rating on the shares. The firm notes ...

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

Morgan Stanley raised the firm’s price target on Gilead (GILD) to $135 from $130 and keeps an Overweight rating on the shares. The company ...

Pharmaceutical stocks are making headlines today, after two U.S.-based sector heavyweights stepped into the earnings ...

A Cardington man has been indicted on 40 counts of pandering sexually oriented materials involving minors. A Morrow County ...

The Handmaid’s Tale season 6, episode 5, cranks up the tension to an all-time high, leaving us dangling on a cliffhanger that will have you biting your nails. June, who’s been relentlessly fighting ...